Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~
Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
